ARCHIVES

Risk-Benefit Analysis Advised Prior To Hormone Therapy

This article is from The Cancer Letter archive.

Vol. 33 No. 8 | August 27, 2010

Download PDF Visit The Full Archive

Related Articles

US Appeals Court Dismisses Fisher’s Privacy Act Suit Supporting Femara

January 10, 1997

House Committee To Examine Personal Genetic Test Kits

May 21, 2010

Obey Insists NCI Pressured IARC Into Softening Report On Benzene Risk

August 20, 1982

Push to Get Exceptions, Adjustments For Clinical Research In DRG Regulations Gaining Momentum

July 22, 1983

Genetronics Phase II Trials For Head & Neck Completed.

May 4, 2001

NCI T BE More Flexible In Funding RFAs Above Paylines

June 23, 1989